false
0001388658
0001388658
2026-11-10
2026-11-10
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
November 10, 2026
iRhythm Holdings, Inc.
(Exact name of Registrant as specified in its
charter)
| Delaware |
001-37918 |
41-3421287 |
(State or other jurisdiction of
incorporation or organization) |
(Commission
File Number) |
(I.R.S. Employer
Identification Number) |
699 8th Street, Suite 600
San Francisco, California 94103
(Address of principal executive office) (Zip
Code)
(415) 632-5700
(Registrant’s telephone number, including
area code)
N/A
(Former Name or Former Address, if Changed Since
Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading Symbol |
Name of each exchange on which registered |
| Common Stock, Par Value $0.001 Per Share |
IRTC |
The NASDAQ Global Select Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ¨
Item 7.01. Regulation FD Disclosure.
On November 11, 2026, iRhythm Holdings, Inc.,
a Delaware corporation (the “Company”), issued a press release announcing the share repurchase program described under Item
8.01 below. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 7.01, including Exhibit
99.1 to this Current Report on Form 8-K, is being furnished and shall not be deemed “filed” for purposes of Section 18 of
the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section,
nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act,
except as expressly set forth by specific reference in such a filing.
Item 8.01. Other Events.
On November 10, 2026, the board of directors of
the Company approved a share repurchase program with authorization to purchase up to $200.0 million of the Company’s outstanding
common stock.
Repurchases under the program may be made in the
open market, in privately negotiated transactions, through accelerated share repurchase transactions or by other methods, with the amount
and timing of repurchases to be determined at the Company’s discretion, depending on market conditions and corporate needs. Open
market repurchases will be structured to occur in accordance with applicable federal and state securities laws, including within the pricing
and volume conditions of Rule 10b-18 under the Exchange Act. The Company may also, from time to time, enter into Rule 10b5-1 plans to
facilitate repurchases of its shares under this authorization. This program does not obligate the Company to repurchase any particular
dollar amount or number of shares of common stock and may be modified, suspended or terminated at any time at the discretion of its board
of directors. The Company expects to fund repurchases with existing cash and cash equivalents and ongoing cash from operations.
Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report
on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation
statements regarding the amount, timing, methods and sources of funding of repurchases under the share repurchase program and the structure
of such repurchases. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other
important factors that may cause actual events or results to differ materially from those expressed or implied by the forward-looking
statements, including, but not limited to, risks relating to the fact that common stock repurchases may not be conducted in the timeframe
or in the manner the Company expects, or at all, and the important factors discussed under the caption “Risk Factors” in the
Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed with the Securities and Exchange Commission
(the “SEC”) on November 5, 2026, and the Company’s other filings with the SEC. These factors could cause actual results
to differ materially from those indicated by the forward-looking statements made in this Current Report on Form 8-K. Any such forward-looking
statements represent management’s estimates as of the date of this Current Report on Form 8-K. While the Company may elect to update
such forward-looking statements at some point in the future, the Company disclaims any obligation to do so, even if subsequent events
cause its views to change.
Item 9.01 Financial Statements and Exhibits
| Exhibit No.
|
|
Description |
| 99.1 |
|
Press release issued by iRhythm Holdings, Inc., dated November 11,
2026. |
| 104 |
|
Cover Page Interactive Data File (formatted as
Inline XBRL) |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
| |
IRHYTHM HOLDINGS, INC. |
| |
|
|
| Date: November 12, 2026 |
By: |
/s/ Daniel Wilson |
| |
|
Daniel Wilson |
| |
|
Chief Financial Officer |
Exhibit 99.1
iRhythm Announces
Approval of $200 Million Share Repurchase Program
SAN FRANCISCO, November
11, 2026 - iRhythm Holdings, Inc. (Nasdaq: IRTC), a leading digital health care company with a mission to create trusted solutions
that detect, predict, and prevent disease, today announced that on November 10, 2026, its Board of Directors approved a share repurchase
program with authorization to purchase up to $200 million of the company’s outstanding common stock.
The approval reflects
iRhythm’s confidence in the continued strength of its core business, as well as its significant new growth opportunities from the
addition of the recently acquired VitalConnect business.
Repurchases under the
program may be made in the open market, in privately negotiated transactions, through accelerated share repurchase transactions or by
other methods, with the amount and timing of repurchases to be determined at the company’s discretion, depending on market conditions
and corporate needs. Open market repurchases will be structured to occur in accordance with applicable federal and state securities laws,
including within the pricing and volume conditions of Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The company
may also, from time to time, enter into Rule 10b5-1 plans to facilitate repurchases of its shares under this authorization. This program
does not obligate the company to repurchase any particular dollar amount or number of shares of common stock and may be modified, suspended
or terminated at any time at the discretion of its Board of Directors.
The company expects
to fund repurchases with existing cash and cash equivalents and ongoing cash from operations.
About iRhythm Holdings,
Inc.
iRhythm is a leading digital health
care company with a mission to create trusted solutions that detect, predict, and prevent disease. Combining wearable biosensors and
cloud-based data analytics with powerful proprietary algorithms, iRhythm distills data from millions of heartbeats into clinically actionable
information. Through a relentless focus on patient care, iRhythm's vision is to deliver better data, better insights, and better health
for all. For more information, visit www.irhythmtech.com.
Forward-Looking
Statements
This press release contains
forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. An investor can identify these statements
by the fact that they do not relate strictly to historical or current facts. They use words such as ‘anticipate’, ‘estimate’,
‘expect’, ‘intend’, ‘will’, ‘project’, ‘plan’, ‘believe’, ‘target’
and other words and terms of similar meaning in connection with any discussion of future actions or operating or financial performance.
In particular, these statements include, without limitation, statements regarding the amount, timing, methods and sources of funding
of repurchases under the share repurchase program and the structure of such repurchases, as well as statements regarding the continued
strength of our core business and growth opportunities from the VitalConnect acquisition. Such statements are based on current assumptions
that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties,
many of which are beyond our control, include, but are not limited to: risks relating to the fact that common stock repurchases may not
be conducted in the timeframe or in the manner we expect, or at all; risks relating to our ability to successfully integrate the VitalConnect
business and realize the anticipated benefits of the acquisition; intense competition in the markets we compete in; fluctuations in our
operating results; future reimbursement and regulatory conditions; financial market conditions; the execution and effect of our business
strategy; future business decisions made by us and our competitors; and additional risks described in the section entitled “Risk
Factors” and elsewhere in our filings made with the Securities and Exchange Commission, including our Quarterly Report on Form
10-Q for the quarter ended September 30, 2026, filed on November 5, 2026. These forward-looking statements speak only as of the date
of this press release and should not be unduly relied upon. We undertake no obligation to update them except as required by law.
Investor Contact
Francis Pruell
investors@irhythmtech.com
Media Contact
Kassandra Perry
mediarelations@irhythmtech.com